Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our diversified portfolio is designed to make a significant impact on rare peripheral amyloid.
Prothena’s success is driven by our people. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, except ourselves. Our values connect us – you will see and feel them come to life in all we do – together.
At Prothena, our culture reflects our values which are brought to life every day by the following characteristics:
Selfless
Patients come first and we’re in this together. Our environment is collaborative and we measure success through our collective accomplishments.
Courageous
Transformational innovation leads to novel treatments. “Tried-and-true” won’t produce breakthroughs for patients – a pioneering spirit, willingness to accept risk and try new approaches will. Each individual and team is expected to bring their heart, experience and trust on our journey.
Imaginative
We value and encourage a creative approach across all aspects of our work. We challenge ourselves and each other to think beyond what is known and approach our work through a lens of continuous improvement.
Joyful
Humor and heart allow us to tackle the seriousness of our work. Excellence and fun are not at odds – we love what we do and enjoy the journey.
For more information, please visit our website at http://www.prothena.com and follow us on Twitter @ProthenaCorp.
Location: Ireland, Dublin City, Dublin
Employees: 51-200
Founded date: 2012
Investors 1
Date | Name | Website |
- | Sofinnova ... | sofinnova.... |
Mentions in press and media 7
Date | Title | Description | Source |
25.03.2024 | Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biot... | Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharma... | medcitynew... |
20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people w... | Melody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a pan... | dailycamer... |
26.07.2021 | Poster: Development of a Dual Aβ-Tau Vaccine for the Prevent... | 52980 Development of a Dual Aβ-Tau Vaccine for the Prevention of Alzheimer Disease Robin Barbour, Ab... | marketscre... |
11.05.2021 | PROTHENA CORPORATION PLC PROTHENA : ANNOUNCES ACHIEVEMENT O... | DUBLIN, Ireland - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robus... | marketscre... |
19.04.2021 | What’s Next For Prothena Stock After A 9% Rise This Week? | LogoProthena | forbes.com... |
08.11.2017 | Kerrisdale predicts failure for Prothena rare disease medica... | Sahm Adrangi’s Kerrisdale Capital Management, known for its activist short positions, has given Elan... | fiercebiot... |
03.10.2016 | Korean officials launch Hanmi probe in wake of tox rep... | As we reported late last week, Boehringer Ingelheim had to do some explaining about its abrupt... | endpts.com... |